Stock analysis searches answered, part 42 of 43

Pulsenmore pulsenmore ltd. pulsenmore.com

Also searched as: "pulsenmore" | "pulsenmore ltd." | "pulsenmore.com"

For “Pulsenmore pulsenmore ltd. pulsenmore.com”, the matching SEC registrant is Pulsenmore Ltd., which trades as PLSM and files under Central Index Key 2064764. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with Israel as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-21, across 51 filings on record. This is reference material, not trading advice.

Financial trend for Pulsenmore Ltd. from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from 6,188,000 ILS (2023-12-31) to 40,024,000 ILS (2025-12-31), a change of +546.8%; net income (loss) went from -58,567,000 ILS (2023-12-31) to -15,853,000 ILS (2025-12-31), a change of +72.9%; total assets went from 141,826,000 ILS (2024-12-31) to 101,847,000 ILS (2025-12-31), a change of -28.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2064764, tags Assets, ProfitLoss, Revenue; 3 periods shown, dashes mark figures Pulsenmore Ltd. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Pulsenmore Ltd. (CIK 2064764) lists its business address as OMARIM 8, OMER, ISRAEL, which helps confirm you are on the right company’s site.

Current reports. Of the 20 8-K or 6-K reports in Pulsenmore Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-31 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 51 recent EDGAR filings, Pulsenmore Ltd. most often filed 6-K (20), 3 (11), DRS/A (4), 4 (2). A selection from 2026-09-01 to 2026-10-21:

The full record for CIK 2064764 is on the EDGAR company page; the latest 20-F there is dated 2026-03-30 and the oldest filing in the recent index dates from 2025-05-12. Insider trades for Pulsenmore Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Quaker chemical quaker chemical corporation quakerhoughton.com

Also searched as: "quaker chemical" | "quaker chemical corporation" | "quakerhoughton.com"

For “Quaker chemical quaker chemical corporation quakerhoughton.com”, the matching SEC registrant is QUAKER CHEMICAL CORP, which trades as KWR and files under Central Index Key 81362. EDGAR puts it in the “Miscellaneous Products of Petroleum & Coal” industry code with PA as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-23 by QUAKER CHEMICAL CORP (CIK 81362) — source document:

Description The Company was organized in 1918 and incorporated as a Pennsylvania business corporation in 1930. Quaker Houghton is the global leader in industrial process fluids. With a robust presence around the world, including operations in over 25 countries, the Company’s customers include thousands of the world’s most advanced and specialized steel, aluminum, automotive, aerospace, offshore, can, mining, and metalworking companies. Quaker Houghton develops, produces, and markets a broad range of formulated specialty chemical products and offers chemical management services (which we refer to as “Fluidcare TM ”) for various heavy industrial and manufacturing applications throughout its three segments: Americas; Europe, Middle East and Africa (“EMEA”); and Asia/Pacific. The major product lines of Quaker Houghton include metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, surface solutions, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, and rod and wire drawing fluids.

Financial trend for QUAKER CHEMICAL CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.94 billion (2022-12-31) to $1.89 billion (2025-12-31), a change of -2.8%; net income (loss) went from -$15.93 million (2022-12-31) to -$2.49 million (2025-12-31), a change of +84.4%; total assets went from $2.82 billion (2022-12-31) to $2.80 billion (2025-12-31), a change of -0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 81362, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures QUAKER CHEMICAL CORP did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for QUAKER CHEMICAL CORP (CIK 81362) lists its business address as ONE QUAKER PARK, CONSHOHOCKEN, PA, which helps confirm you are on the right company’s site.

Current reports. Of the 109 8-K or 6-K reports in QUAKER CHEMICAL CORP’s recent EDGAR index, the 4 listed here run from 2026-07-30 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 81362 is on the EDGAR company page; the latest 10-K there is dated 2026-02-23 and the oldest filing in the recent index dates from 2015-01-22. Insider trades for QUAKER CHEMICAL CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Rallybio rallybio corporation rallybio.com

Also searched as: "rallybio" | "rallybio corporation" | "rallybio.com"

For “Rallybio rallybio corporation rallybio.com”, the matching SEC registrant is Rallybio Corp, which trades as RLYB and files under Central Index Key 1739410. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Rallybio Holdings, LLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-20, across 295 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-16 by Rallybio Corp (CIK 1739410) — source document:

We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Our lead program, RLYB116, is a differentiated complement component 5 (“C5”) inhibitor with the potential to treat diseases of complement dysregulation. In addition, RLYB332, a long-acting matriptase-2 ("MTP-2") antibody for the treatment of diseases of iron overload, is currently in preclinical development. Recent Developments On March 1, 2026, we entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Candid, a clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rallybio (“Merger Sub”).

Financial trend for Rallybio Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $636,000 (2024-12-31) to $858,000 (2025-12-31), a change of +34.9%; net income (loss) went from -$66.65 million (2022-12-31) to -$8.98 million (2025-12-31), a change of +86.5%; total assets went from $180.44 million (2022-12-31) to $62.26 million (2025-12-31), a change of -65.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1739410, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Rallybio Corp did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Rallybio Corp (CIK 1739410) lists its business address as 234 CHURCH STREET, NEW HAVEN, CT, which helps confirm you are on the right company’s site.

Current reports. Of the 49 8-K or 6-K reports in Rallybio Corp’s recent EDGAR index, the 4 listed here run from 2026-03-31 to 2026-09-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1739410 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2018-05-07. Insider trades for Rallybio Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Rank one computing rank one computing corporation

Also searched as: "rank one computing" | "rank one computing corporation"

For “Rank one computing rank one computing corporation”, the matching SEC registrant is Rank One Computing Corp, which trades as ROC and files under Central Index Key 2077709. EDGAR puts it in the “Services-Prepackaged Software” industry code with CO as its state or country of incorporation; its earlier registered name was Rank One Computing Corp dba ROC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-06, across 77 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-31 by Rank One Computing Corp (CIK 2077709) — source document:

Executive Summary ROC is an independent American artificial intelligence (“AI”) company redefining the global standard for Vision AI in identity, security, and digital forensics. Our Vision AI platform delivers real-time facial recognition, multimodal biometric verification, video analytics, and AI-powered evidence analysis to mission-critical organizations across private and public sectors. ROC’s biometric algorithms are routinely ranked by National Institute of Standards and Technology (“NIST”) as among the most accurate and computationally efficient globally. Our solutions outperform legacy foreign-built systems at a fraction of the cost, with faster deployment and stronger trust. As demand for trusted AI accelerates across law enforcement, defense, and regulated commercial sectors, ROC is scaling rapidly through a growing network of integrators and multi-year deals.

Financial trend for Rank One Computing Corp from annual reports, periods 2024-12-31 to 2025-12-31: revenue went from $13.70 million (2024-12-31) to $16.98 million (2025-12-31), a change of +23.9%; net income (loss) went from -$697,678 (2024-12-31) to -$2.68 million (2025-12-31), a change of -283.7%; total assets went from $6.45 million (2024-12-31) to $6.97 million (2025-12-31), a change of +8.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2077709, tags Assets, NetIncomeLoss, Revenues; 2 periods shown, dashes mark figures Rank One Computing Corp did not tag for that period.

Rank One Computing Corp has 77 filings in its recent EDGAR index, including 1 annual reports and 2 quarterly reports; its newest filing is a 8-K from 2026-10-06.

Current reports. Of the 10 8-K or 6-K reports in Rank One Computing Corp’s recent EDGAR index, the 4 listed here run from 2026-08-19 to 2026-10-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2077709 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2025-08-13. Insider trades for Rank One Computing Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Realpha tech corp realpha tech realpha.com

Also searched as: "realpha tech corp" | "realpha tech" | "realpha.com"

For “Realpha tech corp realpha tech realpha.com”, the matching SEC registrant is reAlpha Tech Corp., which trades as AIRE and files under Central Index Key 1859199. EDGAR puts it in the “Real Estate” industry code with DE as its state or country of incorporation; its earlier registered name was ReAlpha Asset Management Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a S-1 filed 2026-10-22, across 371 filings on record. This is reference material, not trading advice.

Financial trend for reAlpha Tech Corp. from annual reports, periods 2023-04-30 to 2025-12-31: revenue went from $419,412 (2023-04-30) to $4.52 million (2025-12-31), a change of +977.3%; net income (loss) went from -$5.45 million (2023-04-30) to -$17.59 million (2025-12-31), a change of -222.6%; total assets went from $27.42 million (2023-12-31) to $21.72 million (2025-12-31), a change of -20.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1859199, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures reAlpha Tech Corp. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for reAlpha Tech Corp. (CIK 1859199) lists its business address as 6515 LONGSHORE LOOP #100, DUBLIN, OH, which helps confirm you are on the right company’s site.

Current reports. Of the 96 8-K or 6-K reports in reAlpha Tech Corp.’s recent EDGAR index, the 4 listed here run from 2026-08-25 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 371 recent EDGAR filings, reAlpha Tech Corp. most often filed 8-K (96), 424B3 (40), 4 (36), CORRESP (28). A selection from 2026-09-25 to 2026-10-22:

The full record for CIK 1859199 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2021-05-07. Insider trades for reAlpha Tech Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Solstice advanced materials

Also searched as: "solstice advanced materials"

For “Solstice advanced materials”, the matching SEC registrant is Solstice Advanced Materials Inc., which trades as SOLS and files under Central Index Key 2064953. EDGAR puts it in the “Chemicals & Allied Products” industry code with DE as its state or country of incorporation; its earlier registered name was Solstice Advanced Materials, LLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-09-14, across 175 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-19 by Solstice Advanced Materials Inc. (CIK 2064953) — source document:

Solstice Advanced Materials Inc. (“Solstice,” “Solstice Advanced Materials,” “we,” “us,” “our,” or the “Company”) is a global, differentiated advanced materials company and a leading global provider of refrigerants, blowing agents, conversion services for the nuclear energy sector, semiconductor materials, protective fibers and healthcare packaging. We operate through two segments, reported as Refrigerants & Applied Solutions (“RAS”) and Electronic & Specialty Materials (“ESM”). Our business is recognized as an industry innovator as well as a technology and quality leader, supported by some of the industry’s most well-known brands. Our RAS segment is a leading manufacturer of low global warming potential (“LGWP”) refrigerants, blowing agents, solvents, and aerosol materials, as well as conversion services for the nuclear energy sector.

Financial trend for Solstice Advanced Materials Inc. from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from $3.65 billion (2023-12-31) to $3.89 billion (2025-12-31), a change of +6.5%; net income (loss) went from $621.00 million (2023-12-31) to $237.00 million (2025-12-31), a change of -61.8%; total assets went from $5.00 billion (2024-12-31) to $5.67 billion (2025-12-31), a change of +13.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2064953, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures Solstice Advanced Materials Inc. did not tag for that period.

Solstice Advanced Materials Inc. has 175 filings in its recent EDGAR index, including 1 annual reports and 3 quarterly reports; its newest filing is a 4 from 2026-09-14.

Current reports. Of the 16 8-K or 6-K reports in Solstice Advanced Materials Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-20 to 2026-08-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2064953 is on the EDGAR company page; the latest 10-K there is dated 2026-02-19 and the oldest filing in the recent index dates from 2025-05-01. Insider trades for Solstice Advanced Materials Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sprott physical silver sprott physical silver trust

Also searched as: "sprott physical silver" | "sprott physical silver trust"

For “Sprott physical silver sprott physical silver trust”, the matching SEC registrant is Sprott Physical Silver Trust, which trades as PSLV and files under Central Index Key 1494728. EDGAR puts it in the “Commodity Contracts Brokers & Dealers” industry code with Ontario, Canada as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-08-13, across 300 filings on record. This is reference material, not trading advice.

Financial trend for Sprott Physical Silver Trust from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $103.22 million (2022-12-31) to $8.48 billion (2025-12-31), a change of +8113.8%; total assets went from $4.10 billion (2022-12-31) to $15.30 billion (2025-12-31), a change of +273.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1494728, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures Sprott Physical Silver Trust did not tag for that period.

Sprott Physical Silver Trust has 300 filings in its recent EDGAR index, including 16 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-08-13.

Current reports. Of the 88 8-K or 6-K reports in Sprott Physical Silver Trust’s recent EDGAR index, the 4 listed here run from 2025-08-15 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 300 recent EDGAR filings, Sprott Physical Silver Trust most often filed 6-K (88), 425 (65), SUPPL (24), F-X (20). A selection from 2026-01-20 to 2026-03-16:

The full record for CIK 1494728 is on the EDGAR company page; the latest 40-F there is dated 2026-03-16 and the oldest filing in the recent index dates from 2010-07-09. Insider trades for Sprott Physical Silver Trust appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sunshine silver mining sunshine silver mining & sunshinesilvermining.com

Also searched as: "sunshine silver mining" | "sunshine silver mining &" | "sunshinesilvermining.com"

For “Sunshine silver mining sunshine silver mining & sunshinesilvermining.com”, the matching SEC registrant is Sunshine Silver Mining & Refining Co, which trades as SSMR and files under Central Index Key 2091017. EDGAR puts it in the “Gold and Silver Ores” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-19, across 43 filings on record. This is reference material, not trading advice.

Financial trend for Sunshine Silver Mining & Refining Co from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $35,258 (2025-06-30) to $0 (2026-06-30), a change of -100.0%; net income (loss) went from -$7.04 million (2025-06-30) to -$16.72 million (2026-06-30), a change of -137.3%; total assets was tagged only for 2026-06-30 at $336.34 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2091017, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Sunshine Silver Mining & Refining Co did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Sunshine Silver Mining & Refining Co (CIK 2091017) lists its business address as 2209 BIG CREEK ROAD, KELLOGG, ID, which helps confirm you are on the right company’s site.

Current reports. Of the 5 8-K or 6-K reports in Sunshine Silver Mining & Refining Co’s recent EDGAR index, the 4 listed here run from 2026-08-12 to 2026-10-19, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 43 recent EDGAR filings, Sunshine Silver Mining & Refining Co most often filed 3 (13), 4 (12), 8-K (5), SCHEDULE 13G (2). A selection from 2026-06-08 to 2026-08-12:

The full record for CIK 2091017 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-10-21. Insider trades for Sunshine Silver Mining & Refining Co appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tectonic therapeutic tectonic therapeutic inc. tectonictx.com

Also searched as: "tectonic therapeutic" | "tectonic therapeutic inc." | "tectonictx.com"

For “Tectonic therapeutic tectonic therapeutic inc. tectonictx.com”, the matching SEC registrant is Tectonic Therapeutic, Inc., which trades as TECX and files under Central Index Key 1681087. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with NY as its state or country of incorporation; its earlier registered name was AvroBio, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 578 filings on record. This is reference material, not trading advice.

Financial trend for Tectonic Therapeutic, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$105.89 million (2022-12-31) to -$74.15 million (2025-12-31), a change of +30.0%; total assets went from $103.95 million (2022-12-31) to $261.04 million (2025-12-31), a change of +151.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1681087, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Tectonic Therapeutic, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Tectonic Therapeutic, Inc. (CIK 1681087) lists its business address as 490 ARSENAL WAY, WATERTOWN, MA, which helps confirm you are on the right company’s site.

Current reports. Of the 103 8-K or 6-K reports in Tectonic Therapeutic, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-07 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 578 recent EDGAR filings, Tectonic Therapeutic, Inc. most often filed 4 (183), 8-K (103), 3 (38), 10-Q (25). A selection from 2026-10-02 to 2026-10-02:

The full record for CIK 1681087 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2016-08-03. Insider trades for Tectonic Therapeutic, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tela bio tela bio inc. telabio.com

Also searched as: "tela bio" | "tela bio inc." | "telabio.com"

For “Tela bio tela bio inc. telabio.com”, the matching SEC registrant is TELA Bio, Inc., which trades as TELA and files under Central Index Key 1561921. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-19, across 545 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-25 by TELA Bio, Inc. (CIK 1561921) — source document:

Our first portfolio of products, the OviTex Reinforced Tissue Matrix ( “OviTex”) which we first commercialized in the U.S. in July 2016 and in Europe in February 2019, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price. Hernia repair is one of the most common surgeries performed in the U.S., representing approximately 1.2 million procedures annually. Based on the volume weighted average selling price of our OviTex products, we estimate the annual U.S. total addressable market opportunity for our OviTex products to be approximately $1.8 billion. Our OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Financial trend for TELA Bio, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $41.42 million (2022-12-31) to $80.28 million (2025-12-31), a change of +93.8%; net income (loss) went from -$44.30 million (2022-12-31) to -$38.83 million (2025-12-31), a change of +12.3%; total assets went from $67.86 million (2022-12-31) to $81.42 million (2025-12-31), a change of +20.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1561921, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures TELA Bio, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for TELA Bio, Inc. (CIK 1561921) lists its business address as 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, which helps confirm you are on the right company’s site.

Current reports. Of the 93 8-K or 6-K reports in TELA Bio, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-29 to 2026-10-08, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1561921 is on the EDGAR company page; the latest 10-K there is dated 2026-03-25 and the oldest filing in the recent index dates from 2012-12-06. Insider trades for TELA Bio, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tenon medical tenon medical inc. tenonmed.com

Also searched as: "tenon medical" | "tenon medical inc." | "tenonmed.com"

For “Tenon medical tenon medical inc. tenonmed.com”, the matching SEC registrant is Tenon Medical, Inc., which trades as TNON, TNONW and files under Central Index Key 1560293. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22, across 300 filings on record. This is reference material, not trading advice.

Financial trend for Tenon Medical, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $691,000 (2022-12-31) to $3.94 million (2025-12-31), a change of +470.8%; net income (loss) went from -$18.92 million (2022-12-31) to -$12.56 million (2025-12-31), a change of +33.6%; total assets went from $11.09 million (2022-12-31) to $10.76 million (2025-12-31), a change of -3.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1560293, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Tenon Medical, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Tenon Medical, Inc. (CIK 1560293) lists its business address as 104 COOPER CT., LOS GATOS, CA, which helps confirm you are on the right company’s site.

Current reports. Of the 55 8-K or 6-K reports in Tenon Medical, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-31 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 300 recent EDGAR filings, Tenon Medical, Inc. most often filed 4 (57), 8-K (55), 3 (15), EFFECT (14). A selection from 2026-10-05 to 2026-10-16:

The full record for CIK 1560293 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2012-10-16. Insider trades for Tenon Medical, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tiziana life sciences

Also searched as: "tiziana life sciences"

For “Tiziana life sciences”, the matching SEC registrant is Tiziana Life Sciences Ltd, which trades as TLSA and files under Central Index Key 1723069. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Bermuda as its state or country of incorporation; its earlier registered name was Tiziana Life Sciences plc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-21, across 489 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-05-01 by Tiziana Life Sciences Ltd (CIK 1723069) — source document:

We were originally incorporated under the laws of England and Wales on February 11, 1998, with the goal of leveraging the expertise of our management team as well as Napoleone Ferrara, M.D., Arun Sanyal, M.D., Howard Weiner, M.D. and Kevan Herold, M.D., and to acquire and exploit certain intellectual property in biotechnology. We subsequently changed our name to Tiziana Life Sciences plc in April 2014 as a result of the acquisition of Tiziana Pharma Limited in April 2014. On August 20, 2021 we announced that we had formally commenced a strategic plan to change our corporate structure by establishing Tiziana Life Sciences Ltd, a Bermuda-incorporated company, to become the ultimate parent company of the Tiziana Group.

Financial trend for Tiziana Life Sciences Ltd from annual reports, periods 2021-12-31 to 2024-12-31: net income (loss) went from -$23.42 million (2021-12-31) to -$11.86 million (2024-12-31), a change of +49.3%; total assets went from $48.83 million (2021-12-31) to $11.28 million (2024-12-31), a change of -76.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1723069, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures Tiziana Life Sciences Ltd did not tag for that period.

Tiziana Life Sciences Ltd has 489 filings in its recent EDGAR index, including 8 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-10-21.

Current reports. Of the 349 8-K or 6-K reports in Tiziana Life Sciences Ltd’s recent EDGAR index, the 4 listed here run from 2026-09-30 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1723069 is on the EDGAR company page; the latest 20-F there is dated 2026-05-01 and the oldest filing in the recent index dates from 2017-11-30. Insider trades for Tiziana Life Sciences Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Turning point brands

Also searched as: "turning point brands"

For “Turning point brands”, the matching SEC registrant is Turning Point Brands, Inc., which trades as TPB and files under Central Index Key 1290677. EDGAR puts it in the “Tobacco Products” industry code with DE as its state or country of incorporation; its earlier registered name was North Atlantic Holding Company, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-21, across 675 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-02 by Turning Point Brands, Inc. (CIK 1290677) — source document:

Turning Point Brands, Inc. (the “Company,” “we,” “our,” or “us”) is a leading manufacturer, marketer and distributor of branded consumer products. We sell a wide range of products to adult consumers consisting of staple products with our iconic brands Zig-Zag® and Stoker’s®. We primarily compete in the alternative smoking accessories and Other Tobacco Products (“OTP”) industries, among other markets. The alternative smoking accessories market is a dynamic market experiencing robust secular growth driven by cannabinoid legalization in the U.S. and Canada, and positively evolving consumer perception and acceptance in North America. The OTP industry, which consists of non-cigarette tobacco products, exhibited steady consumer unit annualized volumes during the full year period ended 2025 as reported by Management Science Associates, Inc. (“MSAi”) a third-party analytics and information company.

Financial trend for Turning Point Brands, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $11.64 million (2022-12-31) to $58.16 million (2025-12-31), a change of +399.7%; total assets went from $572.11 million (2022-12-31) to $763.75 million (2025-12-31), a change of +33.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1290677, tags Assets, NetIncomeLoss, SalesRevenueNet; 4 periods shown, dashes mark figures Turning Point Brands, Inc. did not tag for that period.

Turning Point Brands, Inc. has 675 filings in its recent EDGAR index, including 13 annual reports and 41 quarterly reports; its newest filing is a 8-K from 2026-09-21.

Current reports. Of the 125 8-K or 6-K reports in Turning Point Brands, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-05 to 2026-09-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1290677 is on the EDGAR company page; the latest 10-K there is dated 2026-03-02 and the oldest filing in the recent index dates from 2004-05-18. Insider trades for Turning Point Brands, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

United states lime & minerals united states lime & minerals uslm.com

Also searched as: "united states lime & minerals" | "united states lime & minerals" | "uslm.com"

For “United states lime & minerals united states lime & minerals uslm.com”, the matching SEC registrant is UNITED STATES LIME & MINERALS INC, which trades as USLM and files under Central Index Key 82020. EDGAR puts it in the “Mining & Quarrying of Nonmetallic Minerals (No Fuels)” industry code with TX as its state or country of incorporation; its earlier registered name was SCOTTISH HERITABLE INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-09-11, across 887 filings on record. This is reference material, not trading advice.

Financial trend for UNITED STATES LIME & MINERALS INC from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $45.43 million (2022-12-31) to $134.28 million (2025-12-31), a change of +195.6%; total assets went from $367.77 million (2022-12-31) to $681.04 million (2025-12-31), a change of +85.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 82020, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures UNITED STATES LIME & MINERALS INC did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for UNITED STATES LIME & MINERALS INC (CIK 82020) lists its business address as 5429 LBJ FREEWAY, DALLAS, TX, which helps confirm you are on the right company’s site.

Current reports. Of the 146 8-K or 6-K reports in UNITED STATES LIME & MINERALS INC’s recent EDGAR index, the 4 listed here run from 2026-02-02 to 2026-07-29, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 887 recent EDGAR filings, UNITED STATES LIME & MINERALS INC most often filed 4 (458), 8-K (146), 10-Q (95), DEF 14A (32). A selection from 2026-07-30 to 2026-09-11:

The full record for CIK 82020 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 1994-02-22. Insider trades for UNITED STATES LIME & MINERALS INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Us goldmining u.s. goldmining inc. usgoldmining.us

Also searched as: "us goldmining" | "u.s. goldmining inc." | "usgoldmining.us"

For “Us goldmining u.s. goldmining inc. usgoldmining.us”, the matching SEC registrant is U.S. GoldMining Inc., which trades as USGO and files under Central Index Key 1947244. EDGAR puts it in the “Gold and Silver Ores” industry code with NV as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-14, across 259 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-20 by U.S. GoldMining Inc. (CIK 1947244) — source document:

We are a United States domiciled exploration stage company and our sole project is currently the Whistler Project. The Whistler Project is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, in Alaska. See “ Item 2. Properties” for further information. We were incorporated on June 30, 2015, in Alaska as “BRI Alaska Corp.” and on August 5, 2015, pursuant to an asset purchase agreement dated July 20, 2015, by and among us, GoldMining Inc. (“ GoldMining ”), Kiska Metals Corporation (“ Kiska ”) and Geoinformatics Alaska Exploration, Inc. (“ Geoinformatics ”), we acquired a 100% interest in the Whistler Project and certain related assets.

Financial trend for U.S. GoldMining Inc. from annual reports, periods 2023-11-30 to 2025-12-31: net income (loss) went from -$9.36 million (2023-11-30) to -$6.99 million (2025-12-31), a change of +25.3%; total assets went from $13.02 million (2023-11-30) to $8.45 million (2025-12-31), a change of -35.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1947244, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures U.S. GoldMining Inc. did not tag for that period.

U.S. GoldMining Inc. has 259 filings in its recent EDGAR index, including 3 annual reports and 10 quarterly reports; its newest filing is a 8-K from 2026-10-14.

Current reports. Of the 76 8-K or 6-K reports in U.S. GoldMining Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-02 to 2026-10-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1947244 is on the EDGAR company page; the latest 10-K there is dated 2026-03-20 and the oldest filing in the recent index dates from 2022-11-04. Insider trades for U.S. GoldMining Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Waton financial waton financial limited waton.com

Also searched as: "waton financial" | "waton financial limited" | "waton.com"

For “Waton financial waton financial limited waton.com”, the matching SEC registrant is Waton Financial Ltd, which trades as WTF and files under Central Index Key 1987363. EDGAR puts it in the “Security & Commodity Brokers, Dealers, Exchanges & Services” industry code with Virgin Islands, British as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 20-F filed 2026-07-31, across 48 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-07-31 by Waton Financial Ltd (CIK 1987363) — source document:

This corporate structure involves unique risks to investors. As a holding company, the Company may rely on dividends from its subsidiaries for cash requirements, including any payment of dividends to its shareholders. The subsidiaries’ ability to pay dividends to the Company may be restricted by the debt the subsidiaries incur on their own or laws and regulations applicable to them. KEY INFORMATION — D. Risk Factors — Risks Related to Our Ordinary Shares— We rely on dividends and other distributions on equity paid by our subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our subsidiaries to make payments may restrict our ability to finance our cash requirements, service debt or make dividends or other distributions to our shareholders.” Completion of the Initial Public Offering (“IPO”) On April 2, 2025, we closed our IPO of 4,375,000 Ordinary Shares at a public offering price of $4.00 per share.

Financial trend for Waton Financial Ltd from annual reports, periods 2023-03-31 to 2026-03-31: revenue went from $5.74 million (2023-03-31) to $11.08 million (2026-03-31), a change of +93.1%; net income (loss) went from $3.08 million (2023-03-31) to -$15.15 million (2026-03-31), a change of -591.8%; total assets went from $32.68 million (2024-03-31) to $54.66 million (2026-03-31), a change of +67.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1987363, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Waton Financial Ltd did not tag for that period.

For reported results, Waton Financial Ltd’s (CIK 1987363) EDGAR record shows no 10-Q in the recent window and its latest annual report (20-F) 2026-07-31.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Waton Financial Ltd (CIK 1987363) lists its business address as 3605-06, 36/F, TOWER 6 THE GATEWAY, HONG KONG, Hong Kong, which helps confirm you are on the right company’s site.

Current reports. Of the 4 8-K or 6-K reports in Waton Financial Ltd’s recent EDGAR index, the 4 listed here run from 2025-04-02 to 2026-04-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1987363 is on the EDGAR company page; the latest 20-F there is dated 2026-07-31 and the oldest filing in the recent index dates from 2023-12-22. Insider trades for Waton Financial Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Xilio therapeutics xilio therapeutics inc. xiliotx.com

Also searched as: "xilio therapeutics" | "xilio therapeutics inc." | "xiliotx.com"

For “Xilio therapeutics xilio therapeutics inc. xiliotx.com”, the matching SEC registrant is Xilio Therapeutics, Inc., which trades as XLO and files under Central Index Key 1840233. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 357 filings on record. This is reference material, not trading advice.

Financial trend for Xilio Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $6.34 million (2024-12-31) to $43.77 million (2025-12-31), a change of +589.9%; net income (loss) went from -$88.22 million (2022-12-31) to -$35.04 million (2025-12-31), a change of +60.3%; total assets went from $139.16 million (2022-12-31) to $154.69 million (2025-12-31), a change of +11.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1840233, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Xilio Therapeutics, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Xilio Therapeutics, Inc. (CIK 1840233) lists its business address as 828 WINTER STREET, WALTHAM, MA, which helps confirm you are on the right company’s site.

Current reports. Of the 65 8-K or 6-K reports in Xilio Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-16 to 2026-08-12, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 357 recent EDGAR filings, Xilio Therapeutics, Inc. most often filed 4 (106), 8-K (65), 3 (40), 10-Q (15). A selection from 2026-08-12 to 2026-10-02:

The full record for CIK 1840233 is on the EDGAR company page; the latest 10-K there is dated 2026-03-23 and the oldest filing in the recent index dates from 2021-01-21. Insider trades for Xilio Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

格林豪泰酒店 greentree hospitality

Also searched as: "格林豪泰酒店" | "greentree hospitality"

For “格林豪泰酒店 greentree hospitality”, the matching SEC registrant is GreenTree Hospitality Group Ltd., which trades as GHG and files under Central Index Key 1724755. EDGAR puts it in the “Hotels & Motels” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-08-25, across 124 filings on record. This is reference material, not trading advice.

Financial trend for GreenTree Hospitality Group Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 1,469,074,275 CNY (2022-12-31) to 1,097,353,393 CNY (2025-12-31), a change of -25.3%; net income (loss) went from -425,153,181 CNY (2022-12-31) to 166,792,024 CNY (2025-12-31), a change of +139.2%; total assets went from 5,683,895,279 CNY (2022-12-31) to 4,786,220,707 CNY (2025-12-31), a change of -15.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1724755, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures GreenTree Hospitality Group Ltd. did not tag for that period.

GreenTree Hospitality Group Ltd. has 124 filings in its recent EDGAR index, including 8 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-08-25.

Current reports. Of the 52 8-K or 6-K reports in GreenTree Hospitality Group Ltd.’s recent EDGAR index, the 4 listed here run from 2025-12-23 to 2026-08-25, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 124 recent EDGAR filings, GreenTree Hospitality Group Ltd. most often filed 6-K (52), CORRESP (13), UPLOAD (9), 20-F (8). A selection from 2026-03-26 to 2026-04-30:

The full record for CIK 1724755 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2017-12-08. Insider trades for GreenTree Hospitality Group Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Calcimedica calcimedica inc. calcimedica.com

Also searched as: "calcimedica" | "calcimedica inc." | "calcimedica.com"

For “Calcimedica calcimedica inc. calcimedica.com”, the matching SEC registrant is CalciMedica, Inc., which trades as CALC and files under Central Index Key 1534133. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was CalciMedica, Inc. /DE/. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-16 (this view begins at filings dated on or before 2026-09-28), across 530 filings on record. This is reference material, not trading advice.

Financial trend for CalciMedica, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from -$7.80 million (2025-09-30) to -$7.65 million (2026-06-30), a change of +1.9%; total assets went from $14.91 million (2025-09-30) to $19.50 million (2026-06-30), a change of +30.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1534133, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures CalciMedica, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for CalciMedica, Inc. (CIK 1534133) lists its business address as 505 COAST BOULEVARD SOUTH, LA JOLLA, CA, which helps confirm you are on the right company’s site.

Current reports. Of the 72 8-K or 6-K reports in CalciMedica, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-07 to 2026-08-27, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 530 recent EDGAR filings, CalciMedica, Inc. most often filed 4 (231), 8-K (72), 3 (29), 10-Q (18). A selection from 2026-09-28 to 2026-09-30:

The full record for CIK 1534133 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2011-11-08. One example from this record is the 4 filed 2026-10-05 (document). Insider trades for CalciMedica, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Insulet * * *

Also searched as: "insulet"; "insulet" * * *

For “Insulet * * *”, the matching SEC registrant is INSULET CORP, which trades as PODD and files under Central Index Key 1145197. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-05, across 1001 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-18 by INSULET CORP (CIK 1145197) — source document:

Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod ® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH ® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”). We also produce pods for Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy. Market Opportunity: Management of Diabetes Diabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body’s inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels.

Financial trend for INSULET CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.31 billion (2022-12-31) to $2.71 billion (2025-12-31), a change of +107.5%; net income (loss) went from $4.60 million (2022-12-31) to $247.10 million (2025-12-31), a change of +5271.7%; total assets went from $2.25 billion (2022-12-31) to $3.19 billion (2025-12-31), a change of +41.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1145197, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures INSULET CORP did not tag for that period.

INSULET CORP has 1001 filings in its recent EDGAR index, including 11 annual reports and 34 quarterly reports; its newest filing is a 4 from 2026-10-05.

Current reports. Of the 147 8-K or 6-K reports in INSULET CORP’s recent EDGAR index, the 4 listed here run from 2026-08-05 to 2026-09-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1145197 is on the EDGAR company page; the latest 10-K there is dated 2026-02-18 and the oldest filing in the recent index dates from 2015-08-12. Insider trades for INSULET CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Jayud global logistics limited jayud global logistics jayud.com

Also searched as: "jayud global logistics limited" | "jayud global logistics" | "jayud.com"

For “Jayud global logistics limited jayud global logistics jayud.com”, the matching SEC registrant is Jayud Global Logistics Ltd, which trades as JYD and files under Central Index Key 1938186. EDGAR puts it in the “Arrangement of Transportation of Freight & Cargo” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 3 filed 2026-07-06, across 109 filings on record. This is reference material, not trading advice.

On September 6, 2022, the Company and the shareholders of JYD WLKJ, collectively referred to as the “Initial Shareholders,” entered into certain reorganization agreements (the “Agreements”). On September 6, 2022, the Initial Shareholders transferred their equity interests in JYD WLKJ to JYD HK, a wholly owned subsidiary of the Company in exchange for 15,829,600 ordinary shares issued by the Company to the Initial Shareholders. Therefore, September 6, 2022, was established as the date on which the reorganization was completed. The Company entered into a supplemental agreement (the “Supplemental Agreement”) with the Initial Shareholders on September 7, 2022. This Supplemental Agreement stipulated that if the IPO was successfully completed within one year of the reorganization date, the Company would pay RMB 35 million to the Initial Shareholders; otherwise, no payment would be made. 54 In January and February 2023, anticipating the imminent completion of the IPO, the Company voluntarily settled and made the payment of RMB 35 million to the Initial Shareholders pursuant to the Agreements and the Supplemental Agreement.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Jayud Global Logistics Ltd (CIK 1938186) lists its business address as 4TH FLOOR, BUILDING 4, SHATOUJIAO FTZ, SHENZHEN, which helps confirm you are on the right company’s site.

Updated Oct 25, 2026 ET

Lakewoodamedex biotherapeutics

Also searched as: "lakewoodamedex biotherapeutics"

What this search refers to. “Lakewoodamedex biotherapeutics” refers to Lakewood-Amedex, a private U.S. biotechnology company developing anti-infective compounds; private biotechs appear in EDGAR only if they file a Form D. Official source: efts.sec.gov.

No SEC filer could be matched to “Lakewoodamedex biotherapeutics” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Lakewoodamedex biotherapeutics”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “lakewoodamedex” (search terms considered: lakewoodamedex, biotherapeutics).

EDGAR’s company index has 0 entities whose registered name contains the word “lakewoodamedex”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “lakewoodamedex” 0, “biotherapeutics” 98. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “biotherapeutics”: A2 BIOTHERAPEUTICS, INC. (CIK 1828750), ABBOTT BIOTHERAPEUTICS CORP (CIK 1441848), ADOLORE BIOTHERAPEUTICS, INC. (CIK 1904161). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “lakewoodamedex” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Medicus pharma

Also searched as: "medicus pharma"

For “Medicus pharma”, the matching SEC registrant is Medicus Pharma Ltd., which trades as MDCX, MDCXW and files under Central Index Key 1997296. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Ontario, Canada as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 339 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-25 by Medicus Pharma Ltd. (CIK 1997296) — source document:

On November 15, 2024, we completed our initial public offering in the United States and our common shares and our outstanding public warrants to purchase common shares, issued as a component of the units sold by the Company in its U.S. initial public offering with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"), began trading on Nasdaq under the symbols "MDCX" and "MDCXW", respectively. Effective on February 21, 2025, the Company's common shares were voluntarily delisted from the TSXV. The common shares continue to be listed on Nasdaq. On August 29, 2025, we completed the acquisition of 98.6% of the issued and outstanding shares of Antev for aggregate consideration consisting of approximately US$2.97 million in cash and 1,603,164 common shares of Medicus, pursuant to a securities exchange agreement among Medicus, Antev and certain securityholders of Antev, dated as of June 29, 2025, as amended.

Financial trend for Medicus Pharma Ltd. from annual reports, periods 2023-12-31 to 2025-12-31: net income (loss) went from -$5.31 million (2023-12-31) to -$47.28 million (2025-12-31), a change of -789.6%; total assets went from $1.89 million (2023-12-31) to $10.06 million (2025-12-31), a change of +431.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1997296, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Medicus Pharma Ltd. did not tag for that period.

Medicus Pharma Ltd. has 339 filings in its recent EDGAR index, including 2 annual reports and 5 quarterly reports; its newest filing is a 8-K from 2026-10-23.

Current reports. Of the 40 8-K or 6-K reports in Medicus Pharma Ltd.’s recent EDGAR index, the 4 listed here run from 2026-09-14 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1997296 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-29 and the oldest filing in the recent index dates from 2023-10-13. Insider trades for Medicus Pharma Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Nuveen churchill direct

Also searched as: "nuveen churchill direct"

For “Nuveen churchill direct”, the matching SEC registrant is Nuveen Churchill Direct Lending Corp., which trades as NCDL and files under Central Index Key 1737924. EDGAR puts it in the “no SIC description” industry code with MD as its state or country of incorporation; its earlier registered name was Nuveen Churchill BDC INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-09-15, across 355 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-26 by Nuveen Churchill Direct Lending Corp. (CIK 1737924) — source document:

We are a specialty finance company focused primarily on investing in senior secured loans to private equity-owned U.S. middle market companies. We are externally managed by our Adviser, Churchill DLC Advisor LLC, and through our Sub-Advisers, Churchill Asset Management LLC and Nuveen Asset Management. Our Adviser and our Sub-Advisers are affiliates and subsidiaries of Nuveen, the investment management division of TIAA and one of the largest asset managers globally. We invest in directly originated senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity, as we believe these loans offer us more attractive risk-adjusted returns and stronger protections than investments in the traditional public debt capital markets.

Financial trend for Nuveen Churchill Direct Lending Corp. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $17.29 million (2022-12-31) to $65.61 million (2025-12-31), a change of +279.6%; total assets went from $1.25 billion (2022-12-31) to $2.05 billion (2025-12-31), a change of +63.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1737924, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Nuveen Churchill Direct Lending Corp. did not tag for that period.

Nuveen Churchill Direct Lending Corp. has 355 filings in its recent EDGAR index, including 6 annual reports and 20 quarterly reports; its newest filing is a 4 from 2026-09-15.

Current reports. Of the 83 8-K or 6-K reports in Nuveen Churchill Direct Lending Corp.’s recent EDGAR index, the 4 listed here run from 2026-05-07 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1737924 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2018-04-19. Insider trades for Nuveen Churchill Direct Lending Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Nuwellis nuwellis inc. nuwellis.com

Also searched as: "nuwellis" | "nuwellis inc." | "nuwellis.com"

For “Nuwellis nuwellis inc. nuwellis.com”, the matching SEC registrant is Nuwellis, Inc., which trades as NUWE and files under Central Index Key 1506492. EDGAR puts it in the “Electromedical & Electrotherapeutic Apparatus” industry code with DE as its state or country of incorporation; its earlier registered name was CHF Solutions, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 1000 filings on record. This is reference material, not trading advice.

Financial trend for Nuwellis, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $8.54 million (2022-12-31) to $8.27 million (2025-12-31), a change of -3.2%; net income (loss) went from -$14.53 million (2022-12-31) to -$17.52 million (2025-12-31), a change of -20.6%; total assets went from $24.67 million (2022-12-31) to $6.12 million (2025-12-31), a change of -75.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1506492, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Nuwellis, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Nuwellis, Inc. (CIK 1506492) lists its business address as 12988 VALLEY VIEW ROAD, EDEN PRAIRIE, MN, which helps confirm you are on the right company’s site.

Current reports. Of the 241 8-K or 6-K reports in Nuwellis, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-03 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1000 recent EDGAR filings, Nuwellis, Inc. most often filed 4 (265), 8-K (241), CORRESP (44), 10-Q (41). A selection from 2026-08-14 to 2026-09-18:

The full record for CIK 1506492 is on the EDGAR company page; the latest 10-K there is dated 2026-03-11 and the oldest filing in the recent index dates from 2013-01-28. Insider trades for Nuwellis, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Oceanlight acquisition

Also searched as: "oceanlight acquisition"

For “Oceanlight acquisition”, the matching SEC registrant is OceanLight Acquisition Corp, which trades as OCLT, OCLTR, OCLTU, OCLTW and files under Central Index Key 2137679. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-10-02, across 21 filings on record. This is reference material, not trading advice.

Deal and listing documents for OceanLight Acquisition Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 5 such filings (424B4, 425, S-1, S-1/A) appear in its recent index, the newest dated 2026-09-30.

Current reports. Of the 5 8-K or 6-K reports in OceanLight Acquisition Corp’s recent EDGAR index, the 4 listed here run from 2026-08-14 to 2026-09-30, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 21 recent EDGAR filings, OceanLight Acquisition Corp most often filed 8-K (5), 3 (5), S-1/A (2), 10-Q (1). A selection from 2026-09-08 to 2026-10-02:

The full record for CIK 2137679 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-06-16. Insider trades for OceanLight Acquisition Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Starlink ai acquisition

Also searched as: "starlink ai acquisition"

For “Starlink ai acquisition”, the matching SEC registrant is Starlink AI Acquisition Corp, which trades as OTAI, OTAI-RI, OTAI-UN and files under Central Index Key 2094076. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-09-14, across 25 filings on record. This is reference material, not trading advice.

Financial trend for Starlink AI Acquisition Corp from quarterly and annual reports (three-month periods), periods 2026-04-30 to 2026-07-31: net income (loss) went from -$32,856 (2026-04-30) to $707,825 (2026-07-31), a change of +2254.3%; total assets went from $718,184 (2026-04-30) to $107.01 million (2026-07-31), a change of +14799.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2094076, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Starlink AI Acquisition Corp did not tag for that period.

Deal and listing documents for Starlink AI Acquisition Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 5 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-05-08.

Current reports. Of the 3 8-K or 6-K reports in Starlink AI Acquisition Corp’s recent EDGAR index, the 3 listed here run from 2026-05-13 to 2026-06-02, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 25 recent EDGAR filings, Starlink AI Acquisition Corp most often filed 3 (5), SCHEDULE 13G (4), 8-K (3), S-1/A (3). A selection from 2026-06-18 to 2026-09-14:

The full record for CIK 2094076 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-11-07. Insider trades for Starlink AI Acquisition Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tenon medical

Also searched as: "tenon medical"

For “Tenon medical”, the matching SEC registrant is Tenon Medical, Inc., which trades as TNON, TNONW and files under Central Index Key 1560293. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22 (this view begins at filings dated on or before 2026-09-09), across 300 filings on record. This is reference material, not trading advice.

Financial trend for Tenon Medical, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $1.17 million (2025-09-30) to $1.28 million (2026-06-30), a change of +9.0%; net income (loss) went from -$3.34 million (2025-09-30) to -$4.05 million (2026-06-30), a change of -21.3%; total assets went from $10.37 million (2025-09-30) to $9.92 million (2026-06-30), a change of -4.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1560293, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Tenon Medical, Inc. did not tag for that period.

Tenon Medical, Inc. has 300 filings in its recent EDGAR index, including 4 annual reports and 14 quarterly reports; its newest filing is a 8-K from 2026-10-22.

Current reports. Of the 55 8-K or 6-K reports in Tenon Medical, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-24 to 2026-08-24, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 300 recent EDGAR filings, Tenon Medical, Inc. most often filed 4 (57), 8-K (55), 3 (15), EFFECT (14). A selection from 2026-09-08 to 2026-09-21:

The full record for CIK 1560293 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2012-10-16. One example from this record is the 3 filed 2026-10-09 (document). Insider trades for Tenon Medical, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Turbogen turbogen ltd turbogenchp.com

Also searched as: "turbogen" | "turbogen ltd" | "turbogenchp.com"

For “Turbogen turbogen ltd turbogenchp.com”, the matching SEC registrant is Turbogen Ltd., which trades as TRBG and files under Central Index Key 2088375. EDGAR puts it in the “Electric & Other Services Combined” industry code with Israel as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-16, across 30 filings on record. This is reference material, not trading advice.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Turbogen Ltd. (CIK 2088375) lists its business address as 22 EFAL STREET, PETACH TIKVA, which helps confirm you are on the right company’s site.

Current reports. Of the 4 8-K or 6-K reports in Turbogen Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-31 to 2026-10-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 30 recent EDGAR filings, Turbogen Ltd. most often filed 3 (12), 6-K (4), F-1/A (4), EFFECT (2). A selection from 2026-08-31 to 2026-10-16:

The full record for CIK 2088375 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-12-12. Insider trades for Turbogen Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cg oncology

Also searched as: "cg oncology"

For “Cg oncology”, the matching SEC registrant is CG Oncology, Inc., which trades as CGON and files under Central Index Key 1991792. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-19, across 243 filings on record. This is reference material, not trading advice.

Financial trend for CG Oncology, Inc. from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from $204,000 (2023-12-31) to $4.04 million (2025-12-31), a change of +1880.4%; net income (loss) went from -$48.61 million (2023-12-31) to -$161.00 million (2025-12-31), a change of -231.2%; total assets went from $199.30 million (2023-12-31) to $791.59 million (2025-12-31), a change of +297.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1991792, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 3 periods shown, dashes mark figures CG Oncology, Inc. did not tag for that period.

CG Oncology, Inc. has 243 filings in its recent EDGAR index, including 3 annual reports and 8 quarterly reports; its newest filing is a 4 from 2026-10-19.

Current reports. Of the 29 8-K or 6-K reports in CG Oncology, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-08 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 243 recent EDGAR filings, CG Oncology, Inc. most often filed 4 (76), 144 (45), 8-K (29), 3 (16). A selection from 2026-09-21 to 2026-10-19:

The full record for CIK 1991792 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2023-10-27. Insider trades for CG Oncology, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lightwave logic

Also searched as: "lightwave logic"

For “Lightwave logic”, the matching SEC registrant is Lightwave Logic, Inc., which trades as LWLG and files under Central Index Key 1325964. EDGAR puts it in the “Miscellaneous Plastics Products” industry code with NV as its state or country of incorporation; its earlier registered name was THIRD-ORDER NANOTECHNOLOGIES INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 3 filed 2026-10-01, across 707 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-20 by Lightwave Logic, Inc. (CIK 1325964) — source document:

Lightwave Logic, Inc. is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (“EO”) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Our Perkinamine® family of EO polymer materials is engineered for integration into silicon photonics (“SiPh”) and other photonic integrated circuit (“PIC”) platforms. When incorporated into device architectures, these materials are designed to support high-speed, high-bandwidth optical modulation with lower drive voltage requirements relative to certain conventional silicon-based approaches and certain other traditional photonic material systems, including III-V–based compound semiconductor technologies. The electro-optic properties of these materials can allow shorter interaction lengths in modulator designs, which can contribute to more compact device footprints and increased integration density.

Financial trend for Lightwave Logic, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $40,502 (2023-12-31) to $236,855 (2025-12-31), a change of +484.8%; net income (loss) went from -$17.23 million (2022-12-31) to -$20.31 million (2025-12-31), a change of -17.9%; total assets went from $29.26 million (2022-12-31) to $79.19 million (2025-12-31), a change of +170.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1325964, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Lightwave Logic, Inc. did not tag for that period.

Lightwave Logic, Inc. has 707 filings in its recent EDGAR index, including 18 annual reports and 56 quarterly reports; its newest filing is a 3 from 2026-10-01.

Current reports. Of the 156 8-K or 6-K reports in Lightwave Logic, Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-21 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1325964 is on the EDGAR company page; the latest 10-K there is dated 2026-03-20 and the oldest filing in the recent index dates from 2005-04-27. Insider trades for Lightwave Logic, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Resideo spruce

Also searched as: "resideo" "spruce"

What this search refers to. “Resideo spruce” pairs Resideo Technologies (NYSE: REZI, an SEC filer) with “Spruce”, which is not one of its registered subsidiaries in EDGAR; Resideo’s own 10-K and press releases are where any product or deal by that name would be reported. Official source: www.sec.gov.

No SEC filer could be matched to “Resideo spruce” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Resideo spruce”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “resideo” (search terms considered: resideo, spruce).

EDGAR’s company index has 1 entities whose registered name contains the word “resideo”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “resideo” 1, “spruce” 92. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “resideo”: RESIDEO TECHNOLOGIES, INC. (CIK 1740332); containing “spruce”: 18TH & SPRUCE LLC (CIK 1785454), 2500 SPRUCE LLC (CIK 1982982), 3908 SPRUCE 2, A SERIES OF SUN ROOM FUNDS, LLC (CIK 1722815). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “resideo” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Retension pharmaceuticals

Also searched as: "retension pharmaceuticals"

For “Retension pharmaceuticals”, the matching SEC registrant is Retension Pharmaceuticals, Inc., which trades as RTSN and files under Central Index Key 2002988. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 43 filings on record. This is reference material, not trading advice.

Retension Pharmaceuticals, Inc. has 43 filings in its recent EDGAR index; its newest filing is a 8-K from 2026-10-23.

Current reports. Of the 2 8-K or 6-K reports in Retension Pharmaceuticals, Inc.’s recent EDGAR index, the 2 listed here run from 2026-10-13 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 43 recent EDGAR filings, Retension Pharmaceuticals, Inc. most often filed 4 (11), 3 (10), SCHEDULE 13G (3), DRS/A (3). A selection from 2026-10-15 to 2026-10-22:

The full record for CIK 2002988 is on the EDGAR company page and the oldest filing in the recent index dates from 2023-12-05. Insider trades for Retension Pharmaceuticals, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sable offshore

Also searched as: "sable offshore"

For “Sable offshore”, the matching SEC registrant is Sable Offshore Corp., which trades as SOC and files under Central Index Key 1831481. EDGAR puts it in the “Crude Petroleum & Natural Gas” industry code with DE as its state or country of incorporation; its earlier registered name was Flame Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-19, across 380 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-27 by Sable Offshore Corp. (CIK 1831481) — source document:

References in this section to “we,” “our” and “us” generally refer to Legacy Sable prior to the Business Combination and Sable after the Business Combination. Overview Sable Offshore Corp. (“Sable”) (formerly known as Flame Acquisition Corp. or “Flame”) was a blank check company originally incorporated on October 16, 2020 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses or entities. On March 1, 2021, Flame consummated an initial public offering (the “Flame IPO”), after which its securities began trading on the New York Stock Exchange (“NYSE”). On November 2, 2022, Flame entered into that certain Agreement and Plan of Merger (the “Merger Agreement”), dated November 2, 2022 (amended on December 22, 2022 and June 30, 2023), by and among Flame, Sable Offshore Holdings LLC, a Delaware limited liability company (“Holdco”), and Sable Offshore Corp., a Texas corporation and a wholly owned subsidiary of Holdco (“Legacy Sable”).

Financial trend for Sable Offshore Corp. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2023-12-31) to $0 (2025-12-31); net income (loss) went from -$2.59 million (2022-12-31) to -$410.16 million (2025-12-31), a change of -15730.6%; total assets went from $290.91 million (2022-12-31) to $1.74 billion (2025-12-31), a change of +498.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1831481, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Sable Offshore Corp. did not tag for that period.

Sable Offshore Corp. has 380 filings in its recent EDGAR index, including 5 annual reports and 17 quarterly reports; its newest filing is a SCHEDULE 13G from 2026-10-19.

Current reports. Of the 84 8-K or 6-K reports in Sable Offshore Corp.’s recent EDGAR index, the 4 listed here run from 2026-07-13 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1831481 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2020-11-30. Insider trades for Sable Offshore Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sable offshore hondo

Also searched as: "sable offshore" hondo

For “Sable offshore hondo”, the matching SEC registrant is Sable Offshore Corp., which trades as SOC and files under Central Index Key 1831481. EDGAR puts it in the “Crude Petroleum & Natural Gas” industry code with DE as its state or country of incorporation; its earlier registered name was Flame Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-19 (this view begins at filings dated on or before 2026-08-07), across 380 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-27 by Sable Offshore Corp. (CIK 1831481) (passage 2, continuing from the earlier excerpt) — source document:

Legacy Sable entered into a Purchase and Sale Agreement (as amended, the “Sable-EM Purchase Agreement”) on November 1, 2022 with Exxon Mobil Corporation (“Exxon”) and Mobil Pacific Pipeline Company (“MPPC,” and together with Exxon, “EM”) pursuant to which Legacy Sable agreed to acquire from EM certain assets constituting the Santa Ynez field in Federal waters offshore California and associated onshore processing and pipeline assets (such “Assets,” as defined in the Sable-EM Purchase Agreement, the “SYU Assets”). On February 15, 2024, Sable’s shares of Common Stock, par value $0.0001 per share (“Common Stock”) and warrants to purchase Common Stock at an exercise price of $11.50 per share (the “Public Warrants”) began trading on NYSE under the symbols, “SOC” and “SOC.WS,” respectively.

Financial trend for Sable Offshore Corp. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $0 (2025-09-30) to $137.12 million (2026-06-30); net income (loss) went from -$110.38 million (2025-09-30) to -$64.22 million (2026-06-30), a change of +41.8%; total assets went from $1.65 billion (2025-09-30) to $1.76 billion (2026-06-30), a change of +6.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1831481, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures Sable Offshore Corp. did not tag for that period.

Sable Offshore Corp. has 380 filings in its recent EDGAR index, including 5 annual reports and 17 quarterly reports; its newest filing is a SCHEDULE 13G from 2026-10-19.

Current reports. Of the 84 8-K or 6-K reports in Sable Offshore Corp.’s recent EDGAR index, the 4 listed here run from 2026-06-10 to 2026-07-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1831481 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2020-11-30. One example from this record is the 8-K filed 2026-08-24 (document). Insider trades for Sable Offshore Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sid secure eft + funds

Also searched as: "sid secure eft" +"funds"

What this search refers to. “SID secure EFT + funds” appears to refer to a payment-service product (secure electronic funds transfer) rather than an issuer; payment providers are supervised by banking or money-transmitter regulators, not EDGAR. Corporate-registry check: OpenCorporates search for “Sid secure eft + funds”.

No SEC filer could be matched to “Sid secure eft + funds” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Sid secure eft funds”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “sid” (search terms considered: sid, secure, eft, funds).

Even the shorter phrase “Sid secure eft” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (sid, secure, eft, funds) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 21 entities whose registered name contains the word “sid”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “sid” 21, “secure” 156, “eft” 8, “funds” 496. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “sid”: ASHWORTH SID (CIK 1499703), BADAKHSH AZAD SID (CIK 2126574), BANON SID (CIK 1335468); containing “secure”: 802 SECURE, INC. (CIK 1705045), AMERICAN SECURE LIVING INC. (CIK 1853450), AMERICAN SECURE LIVING SFR FUND I, LP (CIK 1878689); containing “eft”: CITADEL EFT, INC. (CIK 1473971), EFT BIOTECH HOLDINGS INC (CIK 1450973), EFT TELECOM SYSTEMS INC (CIK 1218605); containing “funds”: 1-800 MUTUAL FUNDS INC (CIK 1073045), 10 FUND I, A SERIES OF CLOUD CAPITAL FUNDS, LP (CIK 1942839), 1001 STEPS FUNDS LP (CIK 1478218). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “sid” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

( aeon biopharma ) or expands or expands to or moves or moves headquarters or new facility or new headquarters or new location or new office or opens or opens office) - stock price - investor relations - financial results

Also searched as: ("aeon biopharma") intitle:(establishes or expands or expands to or moves or moves headquarters or new facility or new headquarters or new location or new office or opens or opens office) -"stock price" -"investor relations" -"financial results" -site:youtube.com -site:reddit.com -site:wikipedia.org -site:apps.apple.com -site:developer.android.com -site:downdetector.com -site:play.google.com

For “( aeon biopharma ) or expands or expands to or moves or moves headquarters or new facility or new headquarters or new location or new office or opens or opens office) - stock price - investor relations - financial results”, the matching SEC registrant is AEON Biopharma, Inc., which trades as AEON and files under Central Index Key 1837607. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Priveterra Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23 (this view begins at filings dated on or before 2026-06-22), across 358 filings on record. This is reference material, not trading advice.

Financial trend for AEON Biopharma, Inc. from annual reports, periods 2020-12-31 to 2021-12-31: net income (loss) was tagged only for 2021-12-31 at $8.20 million; total assets went from $81,000 (2020-12-31) to $276.95 million (2021-12-31), a change of +341813.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1837607, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures AEON Biopharma, Inc. did not tag for that period.

For reported results, AEON Biopharma, Inc.’s (CIK 1837607) latest 10-Q is dated 2026-08-12 and its latest annual report (10-K) 2026-03-30. Earnings releases appear as 8-K Item 2.02 filings; 12 are in the recent index, the newest on 2026-08-12.

Current reports. Of the 86 8-K or 6-K reports in AEON Biopharma, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-09 to 2026-05-14, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 358 recent EDGAR filings, AEON Biopharma, Inc. most often filed 8-K (86), 4 (52), 3 (21), 10-Q (17). A selection from 2026-06-22 to 2026-07-08:

The full record for CIK 1837607 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2020-12-23. One example from this record is the 8-K filed 2026-08-12 (document). Insider trades for AEON Biopharma, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

( apollo global management or apollo global ) and ( johnson & johnson or j&j or depuy synthes or depuy )

Also searched as: ("apollo global management" or "apollo global") and ("johnson & johnson" or "j&j" or "depuy synthes" or "depuy")

A Boolean query linking Apollo Global Management with Johnson & Johnson or its DePuy Synthes orthopaedics unit. Each company named is a separate SEC registrant reporting on its own; filing data as of Oct 25, 2026.

Apollo Global Management, Inc. (APO; investment advice, incorporated in DE): its index shows the 8-K of 2026-09-21 covering 7.01 (regulation fd disclosure); the 8-K of 2026-08-24 covering 7.01 (regulation fd disclosure). Year to 2024-12-31: reported revenue $26.11 billion, bottom line $4.58 billion (10-K, 2026-02-25).

JOHNSON & JOHNSON (JNJ; pharmaceutical preparations, incorporated in NJ): its index shows the 8-K of 2026-10-13 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-08-04 covering 5.02 (departure/election of directors or officers), 9.01 (financial statements and exhibits). Year to 2025-12-28: reported revenue $94.19 billion, bottom line $26.80 billion (10-K, 2026-02-11).

Item 2.02 count (results of operations and financial condition — the item that accompanies an earnings release): APO 29 (latest 2026-10-05), JNJ 36 (latest 2026-10-13).

Apollo is a private-equity and credit investor, while DePuy Synthes is Johnson & Johnson’s orthopaedics business. A deal between them would be disclosed by J&J as a divestiture if it were material, and Apollo’s fund investments are usually described in press releases rather than in its own 8-K filings. J&J’s 10-K reports orthopaedics as part of its MedTech segment, so any change of ownership for DePuy Synthes would also show up there in later years.

Accv stock news

Also searched as: "accv" stock news

For “Accv stock news”, the matching SEC registrant is Accelevation Holdings Corp., which trades as ACCV and files under Central Index Key 2141406. EDGAR puts it in the “Electrical Industrial Apparatus” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-13, across 32 filings on record. This is reference material, not trading advice.

For the latest news, the fastest official source is the filing feed: Accelevation Holdings Corp. (CIK 2141406) filed 2 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-13, and its overall latest filing is a 8-K dated 2026-10-13. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 2 8-K or 6-K reports in Accelevation Holdings Corp.’s recent EDGAR index, the 2 listed here run from 2026-10-01 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 32 recent EDGAR filings, Accelevation Holdings Corp. most often filed 3 (13), 4 (7), 8-K (2), S-1/A (2). A selection from 2026-10-05 to 2026-10-05:

The full record for CIK 2141406 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-06-30. Insider trades for Accelevation Holdings Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Altimmune

Also searched as: "altimmune"

For “Altimmune”, the matching SEC registrant is Altimmune, Inc., which trades as ALT and files under Central Index Key 1326190. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was PHARMATHENE, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-05, across 1002 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-06 by Altimmune, Inc. (CIK 1326190) — source document:

Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Our lead product candidate, pemvidutide (formerly known as ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), alcohol use disorder (“AUD”) and alcohol-associated liver disease (“ALD”). We may also pursue additional indications for pemvidutide that leverage its differentiated clinical profile. Except where the context indicates otherwise, references to “we,” “us,” “our,” “Altimmune”, or the “Company” refer to the company and its subsidiaries. Pemvidutide We obtained pemvidutide as part of the acquisition Spitfire Pharma Inc., in July of 2019. Pemvidutide was designed as a MASH therapeutic based on the understanding that targeting both metabolic and liver-specific effects could lead to an improved and differentiated candidate.

Financial trend for Altimmune, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from -$68,000 (2022-12-31) to $41,000 (2025-12-31), a change of +160.3%; net income (loss) went from -$84.71 million (2022-12-31) to -$88.09 million (2025-12-31), a change of -4.0%; total assets went from $206.93 million (2022-12-31) to $279.93 million (2025-12-31), a change of +35.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1326190, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Altimmune, Inc. did not tag for that period.

Altimmune, Inc. has 1002 filings in its recent EDGAR index, including 16 annual reports and 47 quarterly reports; its newest filing is a 4 from 2026-10-05.

Current reports. Of the 199 8-K or 6-K reports in Altimmune, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-16 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1326190 is on the EDGAR company page; the latest 10-K there is dated 2026-03-06 and the oldest filing in the recent index dates from 2011-01-25. Insider trades for Altimmune, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Anterix

Also searched as: "anterix"

For “Anterix”, the matching SEC registrant is Anterix Inc., which trades as ATEX and files under Central Index Key 1304492. EDGAR puts it in the “Telephone Communications (No Radiotelephone)” industry code with DE as its state or country of incorporation; its earlier registered name was pdvWireless, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-13, across 924 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-06-25 by Anterix Inc. (CIK 1304492) — source document:

Anterix Inc. (“Anterix,” “we,” “our,” or the “Company”) is the nation’s largest holder of licensed 900 MHz spectrum (896-901/935-940 MHz) with coverage spanning the contiguous United States, Hawaii, Alaska, and Puerto Rico. Our mission is to transform critical infrastructure connectivity, commercialize our spectrum assets and deliver advanced intelligent infrastructure solutions, including private broadband networks, tower access, and turnkey connectivity management, to utility and critical infrastructure enterprises seeking to enhance operational efficiency, strengthen grid resilience, and accelerate digital transformation. During fiscal 2026, we evolved our business strategy. Building on our foundational 900 MHz spectrum position, we transitioned from a model focused predominantly on long-term spectrum leasing to a broader operating model.

Financial trend for Anterix Inc. from annual reports, periods 2023-03-31 to 2026-03-31: revenue went from $1.92 million (2023-03-31) to $6.50 million (2026-03-31), a change of +238.8%; net income (loss) went from -$16.32 million (2023-03-31) to $90.64 million (2026-03-31), a change of +655.5%; total assets went from $278.56 million (2023-03-31) to $465.21 million (2026-03-31), a change of +67.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1304492, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Anterix Inc. did not tag for that period.

Anterix Inc. has 924 filings in its recent EDGAR index, including 12 annual reports and 35 quarterly reports; its newest filing is a 4 from 2026-10-13.

Current reports. Of the 119 8-K or 6-K reports in Anterix Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-10 to 2026-09-18, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1304492 is on the EDGAR company page; the latest 10-K there is dated 2026-06-25 and the oldest filing in the recent index dates from 2004-09-27. Insider trades for Anterix Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Citius pharmaceuticals

Also searched as: "citius pharmaceuticals"

For “Citius pharmaceuticals”, the matching SEC registrant is Citius Pharmaceuticals, Inc., which trades as CTXR and files under Central Index Key 1506251. EDGAR puts it in the “Pharmaceutical Preparations” industry code with NV as its state or country of incorporation; its earlier registered name was Trail One, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-08-21, across 636 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2025-12-23 by Citius Pharmaceuticals, Inc. (CIK 1506251) — source document:

Citius Pharmaceuticals, Inc., headquartered in Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products. Our goal generally is to achieve leading market positions by providing therapeutic products that address unmet medical needs yet have a lower development risk than usually is associated with new chemical entities. New formulations of previously approved drugs with substantial existing safety and efficacy data are a core focus. We seek to reduce development and clinical risks associated with drug development, yet still focus on innovative applications. Our strategy centers on products that have intellectual property and regulatory exclusivity protection, while providing competitive advantages over other existing therapeutic approaches.

Financial trend for Citius Pharmaceuticals, Inc. from annual reports, periods 2022-09-30 to 2025-09-30: net income (loss) went from -$33.64 million (2022-09-30) to -$32.54 million (2023-09-30), a change of +3.3%; total assets went from $114.00 million (2022-09-30) to $130.94 million (2025-09-30), a change of +14.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1506251, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Citius Pharmaceuticals, Inc. did not tag for that period.

Citius Pharmaceuticals, Inc. has 636 filings in its recent EDGAR index, including 14 annual reports and 46 quarterly reports; its newest filing is a 8-K from 2026-08-21.

Current reports. Of the 185 8-K or 6-K reports in Citius Pharmaceuticals, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-01 to 2026-08-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1506251 is on the EDGAR company page; the latest 10-K/A there is dated 2026-01-28 and the oldest filing in the recent index dates from 2010-11-23. Insider trades for Citius Pharmaceuticals, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Csr.gfl.co.in

Also searched as: "csr.gfl.co.in" -site:csr.gfl.co.in -site:gfl.co.in -site:facebook.com -site:instagram.com -site:threads.com -site:threads.net -site:linkedin.com -site:x.com -site:twitter.com -site:tiktok.com -site:youtube.com -site:youtu.be -site:reddit.com -site:t.me -site:telegram.me -site:telegram.org -site:pinterest.com -site:vimeo.com

“Csr.gfl.co.in” is a web address rather than a company name. Who operates csr.gfl.co.in is recorded in the domain registration data, which ICANN’s registration-data lookup returns where the registrant has not opted for privacy; that is the official way to tie the site to a legal entity before looking for any securities filings.

No SEC filer could be matched to “Csr.gfl.co.in” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Csr.gfl.co.in”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “csr” (search terms considered: csr, gfl).

EDGAR’s company index has 19 entities whose registered name contains the word “csr”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “csr” 19, “gfl” 6. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “csr”: 1547 CSR - DR FORTRESS R, LLC (CIK 2100042), 1547 CSR- CHICAGO LLC (CIK 1700837), CSR ACQUISITION CORP. (CIK 1818212); containing “gfl”: BCEC-GFL BORROWER GP (CAYMAN), LTD (CIK 1846343), GFL CO-INVEST, L.P. (CIK 1742220), GFL ENVIRONMENTAL HOLDINGS INC. (CIK 1780232). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “csr” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Daxor daxor corporation daxor.com

Also searched as: "daxor" | "daxor corporation" | "daxor.com"

For “Daxor daxor corporation daxor.com”, the matching SEC registrant is DAXOR CORP, which trades as DXR and files under Central Index Key 27367. EDGAR puts it in the “no SIC description” industry code with NY as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 40-8F-2/A filed 2026-10-09 (this view begins at filings dated on or before 2026-06-25), across 736 filings on record. This is reference material, not trading advice.

Financial trend for DAXOR CORP from quarterly and annual reports (three-month periods), periods 2010-09-30 to 2011-09-30: revenue went from $453,281 (2010-09-30) to $340,907 (2011-09-30), a change of -24.8%; net income (loss) went from $2.60 million (2010-09-30) to -$4.18 million (2011-09-30), a change of -260.6%; total assets was tagged only for 2011-09-30 at $88.25 million. Values are as filed and not adjusted for restatements, splits or currency.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for DAXOR CORP (CIK 27367) lists its business address as 107 MECO LANE, OAK RIDGE, TN, which helps confirm you are on the right company’s site.

Current reports. Of the 37 8-K or 6-K reports in DAXOR CORP’s recent EDGAR index, the 4 listed here run from 2024-03-25 to 2025-07-01, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 736 recent EDGAR filings, DAXOR CORP most often filed 4 (267), 10-Q (51), 40-17F2 (38), 8-K (37). A selection from 2026-06-25 to 2026-08-31:

The full record for CIK 27367 is on the EDGAR company page; the latest N-CSR there is dated 2026-08-31 and the oldest filing in the recent index dates from 1995-04-18. One example from this record is the NPORT-P filed 2026-08-31 (document). Insider trades for DAXOR CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Fitness champs fitness champs holdings fitnesschamps.sg

Also searched as: "fitness champs" | "fitness champs holdings" | "fitnesschamps.sg"

For “Fitness champs fitness champs holdings fitnesschamps.sg”, the matching SEC registrant is Fitness Champs Holdings Ltd, which trades as FCHL and files under Central Index Key 2023796. EDGAR puts it in the “Services-Miscellaneous Amusement & Recreation” industry code with Singapore as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-08-27, across 71 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-05-15 by Fitness Champs Holdings Ltd (CIK 2023796) — source document:

Our principal subsidiary, Fitness Champs, was incorporated as an exempt private company limited by shares in Singapore in 2012 under the Singapore Companies Act of 1967, as amended (the “Singapore Companies Act”) under the name of “Fitness Champs Pte. Ltd.” Previously, the business was a sole proprietorship operated by Ms. Lee under the business name “Fitness Champs.” Fitness Champs operates school-based swimming lessons. In 2015, Fitness Aquatics was incorporated as an exempt private company limited by shares company in Singapore under the Singapore Companies Act under the name of “Fitness Champs Aquatics Pte. Ltd.,” mainly to provide private swimming and aquatic sports lessons. In 2020, Fitness Champs won the tender by the Singapore Government (represented by the MOE) to provide swimming lessons to public schools in Singapore as part of the SwimSafer program.

Financial trend for Fitness Champs Holdings Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 2,764,000 SGD (2022-12-31) to 4,150,000 SGD (2025-12-31), a change of +50.1%; net income (loss) went from 663,000 SGD (2022-12-31) to -1,365,000 SGD (2025-12-31), a change of -305.9%; total assets went from 1,619,000 SGD (2023-12-31) to 2,667,000 SGD (2025-12-31), a change of +64.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2023796, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Fitness Champs Holdings Ltd did not tag for that period.

Fitness Champs Holdings Ltd has 71 filings in its recent EDGAR index, including 2 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-08-27.

Current reports. Of the 14 8-K or 6-K reports in Fitness Champs Holdings Ltd’s recent EDGAR index, the 4 listed here run from 2026-06-01 to 2026-08-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2023796 is on the EDGAR company page; the latest 20-F there is dated 2026-05-15 and the oldest filing in the recent index dates from 2024-05-17. Insider trades for Fitness Champs Holdings Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Fluor corporation engineering epc news 2026

Also searched as: "fluor" corporation engineering epc news 2026

For “Fluor corporation engineering epc news 2026”, the matching SEC registrant is FLUOR CORP, which trades as FLR and files under Central Index Key 1124198. EDGAR puts it in the “Heavy Construction Other Than Bldg Const - Contractors” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-08-10, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-17 by FLUOR CORP (CIK 1124198) — source document:

Fluor is dedicated to building a better world by applying our world-class expertise to solve our clients' greatest challenges. We deliver professional and technical solutions that emphasize safety, operational excellence and capital efficiency for our clients. Incorporated in Delaware in September 2000, Fluor and its predecessors have served clients for over 110 years, consistently supporting development and progress. We believe we are poised to continue helping our clients meet similar needs into the foreseeable future. Through our subsidiaries and joint ventures, we stand among the world's leading professional services firms, offering EPC and project management services. We provide th ese services to our clients in diverse industries worldwide including life sciences, advanced technologies and manufacturing, data centers, mining and metals, gas and nuclear derived power, infrastructure, chemicals, LNG, and oil and gas production and fuels.

Financial trend for FLUOR CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $13.74 billion (2022-12-31) to $15.50 billion (2025-12-31), a change of +12.8%; net income (loss) went from $145.00 million (2022-12-31) to -$51.00 million (2025-12-31), a change of -135.2%; total assets went from $6.83 billion (2022-12-31) to $8.24 billion (2025-12-31), a change of +20.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1124198, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures FLUOR CORP did not tag for that period.

For the latest news, the fastest official source is the filing feed: FLUOR CORP (CIK 1124198) filed 122 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-08-07, and its overall latest filing is a 4 dated 2026-08-10. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 122 8-K or 6-K reports in FLUOR CORP’s recent EDGAR index, the 4 listed here run from 2026-04-30 to 2026-08-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1124198 is on the EDGAR company page; the latest 10-K/A there is dated 2026-03-02 and the oldest filing in the recent index dates from 2016-10-05. Insider trades for FLUOR CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Golub capital

Also searched as: "golub capital"

For “Golub capital”, the matching SEC registrant is GOLUB CAPITAL BDC, Inc., which trades as GBDC and files under Central Index Key 1476765. EDGAR puts it in the “no SIC description” industry code with DE as its state or country of incorporation; its earlier registered name was GOLUB CAPITAL INVESTMENT Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-06, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2025-11-18 by GOLUB CAPITAL BDC, Inc. (CIK 1476765) — source document:

We are an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended, or the 1940 Act. In addition, for U.S. federal income tax purposes, we have elected to be treated as a regulated investment company, or RIC, under Subchapter M of the Internal Revenue Code of 1986, as amended, or the Code. We were formed in November 2009 to continue and expand the business of our predecessor, Golub Capital Master Funding LLC, which commenced operations in July 2007. We make investments primarily in one stop loans (a loan that combines characteristics of traditional first lien senior secured loans and second lien or subordinated loans and that are often referred to by other middle market lenders as unitranche loans) and other senior secured loans of U.S. middle-market companies that are, in most cases, sponsored by private equity firms.

Financial trend for GOLUB CAPITAL BDC, Inc. from annual reports, periods 2022-09-30 to 2025-09-30: net income (loss) went from $153.44 million (2022-09-30) to $376.65 million (2025-09-30), a change of +145.5%; total assets went from $5.68 billion (2022-09-30) to $8.98 billion (2025-09-30), a change of +58.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1476765, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures GOLUB CAPITAL BDC, Inc. did not tag for that period.

GOLUB CAPITAL BDC, Inc. has 1000 filings in its recent EDGAR index, including 13 annual reports and 42 quarterly reports; its newest filing is a 8-K from 2026-10-06.

Current reports. Of the 332 8-K or 6-K reports in GOLUB CAPITAL BDC, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-03 to 2026-10-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1476765 is on the EDGAR company page; the latest 10-K there is dated 2025-11-18 and the oldest filing in the recent index dates from 2012-12-17. Insider trades for GOLUB CAPITAL BDC, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Latigo biotherapeutics latigo biotherapeutics inc. latigobio.com

Also searched as: "latigo biotherapeutics" | "latigo biotherapeutics inc." | "latigobio.com"

For “Latigo biotherapeutics latigo biotherapeutics inc. latigobio.com”, the matching SEC registrant is Latigo Biotherapeutics, Inc., which trades as LTGO and files under Central Index Key 2056611. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-09-03, across 40 filings on record. This is reference material, not trading advice.

Financial trend for Latigo Biotherapeutics, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: net income (loss) went from -$25.84 million (2025-06-30) to -$25.80 million (2026-06-30), a change of +0.1%; total assets was tagged only for 2026-06-30 at $64.76 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2056611, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Latigo Biotherapeutics, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Latigo Biotherapeutics, Inc. (CIK 2056611) lists its business address as 1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS, CA, which helps confirm you are on the right company’s site.

Current reports. Of the 2 8-K or 6-K reports in Latigo Biotherapeutics, Inc.’s recent EDGAR index, the 2 listed here run from 2026-08-10 to 2026-09-03, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 40 recent EDGAR filings, Latigo Biotherapeutics, Inc. most often filed 3 (13), 4 (7), SCHEDULE 13G (3), 8-K (2). A selection from 2026-08-13 to 2026-09-03:

The full record for CIK 2056611 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-02-13. Insider trades for Latigo Biotherapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Stz lucky stars

Also searched as: "stz lucky stars" -site:cbrands.com -site:facebook.com -site:instagram.com -site:threads.com -site:threads.net -site:linkedin.com -site:x.com -site:twitter.com -site:tiktok.com -site:youtube.com -site:youtu.be -site:reddit.com -site:t.me -site:telegram.me -site:telegram.org -site:pinterest.com -site:vimeo.com

What this search refers to. “STZ Lucky Stars” does not correspond to an issuer; STZ is the NYSE ticker of Constellation Brands, but no Constellation product or subsidiary called Lucky Stars appears in its SEC filings. Official source: www.sec.gov.

No SEC filer could be matched to “Stz lucky stars” with a single, clear Central Index Key: the phrase “Stz lucky stars” appears in 9 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “stz” (search terms considered: stz, lucky, stars).

In the 9 most relevant full-text hits returned for “Stz lucky stars”, filings range from 2018-04-23 to 2026-04-22. The filers whose documents mention it most often are CONSTELLATION BRANDS, INC. (STZ) (CIK 0000016918) (9 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 2 entities whose registered name contains the word “stz”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “stz” 2, “lucky” 75, “stars” 83. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “stz”: NSDT 2009 STZ LLC (CIK 1937226), NSDT 2011 STZ LLC (CIK 1937251); containing “lucky”: 13 LOOKIN AT LUCKY/FUSAICHI, LLC (CIK 1724108), 13 LUCKY PULPIT-LASTING BEAUTY, LLC (CIK 1634996), 14 LOOKIN AT LUCKY/BRUSH THE RAIL, LLC (CIK 1669764); containing “stars”: 05 CAT THIEF/GOLD IN MY STARS LLC (CIK 1406134), 57 STARS ACTIS 4 INVESTMENT VEHICLE LP INC. (CIK 1566681), 57 STARS GLOBAL OPPORTUNITY FUND (NYSCRF), L.P. (CIK 1834692). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “stz” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Tango therapeutics

Also searched as: "tango therapeutics"

For “Tango therapeutics”, the matching SEC registrant is Tango Therapeutics, Inc., which trades as TNGX and files under Central Index Key 1819133. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was BCTG Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 421 filings on record. This is reference material, not trading advice.

Financial trend for Tango Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $24.86 million (2022-12-31) to $62.38 million (2025-12-31), a change of +150.9%; net income (loss) went from -$108.18 million (2022-12-31) to -$101.59 million (2025-12-31), a change of +6.1%; total assets went from $436.47 million (2022-12-31) to $398.69 million (2025-12-31), a change of -8.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1819133, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Tango Therapeutics, Inc. did not tag for that period.

Tango Therapeutics, Inc. has 421 filings in its recent EDGAR index, including 6 annual reports and 18 quarterly reports; its newest filing is a 8-K from 2026-10-23.

Current reports. Of the 50 8-K or 6-K reports in Tango Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 421 recent EDGAR filings, Tango Therapeutics, Inc. most often filed 4 (114), 8-K (50), 144 (43), 3 (36). A selection from 2026-08-14 to 2026-10-05:

The full record for CIK 1819133 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2020-07-30. Insider trades for Tango Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET